Company

Neumous Inc.

Neumous develops focused ultrasound devices for drug delivery across the blood-brain barrier.

About

Neumous develops non-invasive ultrasound devices to open the blood-brain barrier and deliver therapeutic agents to targeted brain regions. Its technology is intended for conditions including brain tumors and Alzheimer’s disease. Founded in 2022, the company is based in Cheongju-si, South Korea. In July 2025, it raised KRW 9.6 billion in Series A funding from AJU IB Investment, STIC Ventures, SL Investment, IBK Venture Investment, and returning partner FuturePlay.

1Funding rounds

5Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in